Efficacy and safety of maintenance therapy with tegafur for residual lesions after chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
10.3760/cma.j.cn115355-20240516-00242
- VernacularTitle:替吉奥维持治疗局部晚期食管鳞状细胞癌放化疗后残留病灶的效果及安全性
- Author:
Shuai LANG
1
;
Yimin LIU
;
Tingting DONG
;
Junxia HU
;
Lili LIN
;
Delin LIU
;
Lin ZHU
Author Information
1. 江苏省人民医院宿迁医院肿瘤中心，宿迁 223800
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms;
Carcinoma, squamous cell;
Concurrent chemoradiotherapy;
Albumin-conjugated paclitaxel;
Maintenance therapy
- From:
Cancer Research and Clinic
2025;37(8):613-617
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of oral maintenance therapy with tegafur for residual lesions in patients with locally advanced esophageal squamous cell carcinoma (ESCC) after chemoradiotherapy.Methods:A retrospective cohort study was conducted. A total of 38 patients with locally advanced ESCC who had residual lesions after receiving albumin bound paclitaxel combined with platinum chemoradiotherapy from March 2019 to September 2021 in Jiangsu Province Suqian Hospital were selected. All patients were divided into the maintenance treatment group (20 cases) and the non-maintenance treatment group (18 cases) based on whether they received oral maintenance therapy with tegafur after chemoradiotherapy. The progression-free survival (PFS) of both groups was compared and the adverse reactions of the maintenance treatment group were analyzed.Results:There were no statistically significant differences in baseline data between the 2 groups (both P > 0.05). The 1, 2, 3-year PFS rates for the maintenance treatment group were 95.0%, 78.1%, and 58.3%, respectively, with a median PFS time of 33.65 months (95% CI: 29.04-38.26 months); the 1, 2, 3-year PFS rates in the non-maintenance treatment group were 88.9%, 54.5%, and 12.1%, respectively, with a median PFS time of 25.08 months (95% CI: 20.97-29.18 months); there was a statistically significant difference in PFS between the 2 groups ( χ2 = 5.36, P = 0.021). The common adverse reactions in the maintenance treatment group included hematological adverse reactions, hand foot syndrome, decreased appetite, and fatigue. The more common adverse reactions were neutropenia [85.0% (17/20)] and leukopenia [65.0% (13/20)]; 9 cases experienced grade 3-4 adverse reactions, which were relieved by adjusting the dosage or discontinuing the medication. Conclusions:Oral maintenance therapy with tegafur may improve the survival of ESCC patients with residual lesions after chemoradiotherapy and the adverse reactions are controllable.
